Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9378)	3/25/1999 10:48:00 AM
From: Bluegreen	Read Replies (2) \| Respond to of 17367

George, we have gone full circle. I still don't see why you think it is unlikely to replicate Phase II results. In my opinion Baboon study was much greater feat of strength than Meningo. Phase II study. So what is main difference between open label Phase II and Phase III going on now? You say half are getting placebo when they are in G of 8 or more? What does that tell you? Now the other half are getting Neuprex? How do you see that as so much more meaningful than open label Phase II? Is it really that much more of a sample size to mean anything? Why hasn't anybody asked Xoma exactly WHEN and by who mortality requirement was made and if that number was ever changed during trial?